Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.66 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315585 | 1.00 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL29716681 | 1.00 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL1313311 | 1.00 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL458459 | 1.00 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL1315584 | 1.00 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL5767420 | 0.88 | GBA1 (0.58) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL5767421 | 0.88 | GBA1 (0.58) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL5767414 | 0.88 | GBA1 (0.58) | GBA1FUCA1ALDH1A1SLC18A3NPC1 | |
| SCHEMBL21593408 | 0.88 | GBA1 (0.66) | GBA1FUCA1ALDH1A1SLC18A3ACHE | |
| SCHEMBL5999878 | 0.88 | FUCA1 (0.58) | GBA1FUCA1ALDH1A1SLC18A3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11613532-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-03-28 | — | — | US | disclosed |
| EP-4126874-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126875-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2023-02-08 | — | — | EP | disclosed |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2022-11-17 | — | — | US | disclosed |
| EP-4076661-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | Nuevolution A/S (DK) | 2022-10-26 | — | — | EP | disclosed |
| CN-114728170-A | Compounds active on nuclear receptors | 纽韦卢森公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-1206938-A1 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
| EP-1140915-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| US-6096761-A | REACTING A N-SUBSTITUTED 4-METHANOL-3-HYDROXY OR ALKOXY-PIPERIDINE INTERMEDIATE WITH A CARBOXYLIC ACID DERIVATIVES; ADMINISTERING TO AN ANIMAL SUFFERING WITH A CONDITION RELATED TO HAMPERED OR IMPAIRED GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-08-01 | — | — | US | disclosed |
| WO-2000037461-A1 | 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES FOR TREATING GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| EP-1000028-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| EP-0991410-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999002156-A1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| WO-1999002494-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| EP-0880500-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030031-A1 | ESTERS OF 3-HYDROXY-PIPERIDINEMETHANOL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
| US-20220363683-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
| US-11613532-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | GBA1 3643/4885FUCA1 4184/4885ALDH1A1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.